HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW to Review Criteria for Clinical Research Core Hospitals by April

July 29, 2014
BUSINESS AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President

July 28, 2014
ORGANIZATION JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year

July 25, 2014
BUSINESS Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products

July 25, 2014
BUSINESS Astellas Gears Up to Accelerate R&D

July 24, 2014
REGULATORY Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago

July 23, 2014
BUSINESS Disclosure of Payments from Drug Makers to Doctors Delayed

July 22, 2014
BUSINESS Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014

July 18, 2014
BUSINESS Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President

July 17, 2014
BUSINESS Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo

July 16, 2014
BUSINESS Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient

July 15, 2014
BUSINESS “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel

July 14, 2014
REGULATORY Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima

July 14, 2014
BUSINESS Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016

July 11, 2014
BUSINESS Novartis Lays Out New Global Guidelines for Investigator-Led Trials

July 10, 2014
BUSINESS Bayer Yakuhin Sees Cancer Drugs as New Pillar

July 9, 2014
BUSINESS MTPC Aspires to Derive 30% of Sales from Offshore Biz

July 8, 2014
BUSINESS Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.

July 7, 2014
BUSINESS Sawai Preparing to File More Products for US Approval: Exec

July 4, 2014
REGULATORY MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement

July 4, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…